Cabaletta Bio Reports $51M Net Loss and $225M Cash Position for Q2 2026

Cabaletta Bio, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $51.0 million for the quarter, compared to a loss of $45.1 million in the same period last year, reflecting an increase in operational expenses. Total operating expenses for the quarter were $52.0 million, up from $45.9 million in the prior year, driven primarily by increased research and development costs, which rose to $44.4 million from $37.6 million. The increase in R&D expenses was attributed to higher costs associated with clinical trials and manufacturing of preclinical and clinical supplies.

In terms of liquidity, Cabaletta reported cash and cash equivalents of $225.1 million as of June 30, 2026, a substantial increase from $83.0 million at the end of 2025. This increase was largely due to successful financing activities, including the issuance of 51.7 million shares of common stock in May 2026, which generated approximately $140.2 million in net proceeds. The company also raised $28.7 million through its at-the-market offering program during the first half of 2026. Despite these inflows, Cabaletta continues to face substantial operating losses and has expressed concerns regarding its ability to continue as a going concern without additional funding.

Cabaletta's strategic focus remains on advancing its lead product candidate, resecabtagene autoleucel (rese-cel), through its RESET clinical trials aimed at treating various autoimmune diseases. The company has made significant progress in its clinical development program, including the initiation of registrational cohorts for diseases such as dermatomyositis and systemic sclerosis. The FDA has granted multiple designations to rese-cel, including Fast Track and Orphan Drug Designations, which may facilitate its path to market.

Operationally, the company has expanded its manufacturing capabilities by partnering with Lonza Houston Inc. and Cellares Corporation, which are critical for the production of rese-cel. These partnerships are expected to enhance the scalability of manufacturing processes, particularly as the company prepares for potential commercialization. As of June 30, 2026, Cabaletta had a total of 167.7 million shares outstanding, reflecting its ongoing efforts to raise capital and support its clinical and operational initiatives.

Looking ahead, Cabaletta anticipates continued investment in research and development, with expectations of increased expenses as it advances its clinical trials and prepares for regulatory submissions. The company has indicated that it will need to secure additional funding to sustain its operations and meet its strategic goals, emphasizing the importance of its ongoing financing efforts to support its ambitious development pipeline.